Introduction BioRay Biopharmaceutical Co., Ltd., a division of Zhejiang Hisun Pharmaceutical Co., Ltd., is a China-based corporation engaged in the production and distribution of pharmaceutical goods. |
Disease Domain | Count |
---|---|
Neoplasms | 23 |
Immune System Diseases | 12 |
Hemic and Lymphatic Diseases | 8 |
Infectious Diseases | 6 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 17 |
Antibody drug conjugate (ADC) | 6 |
Biosimilar | 6 |
Antibody | 3 |
Fusion protein | 3 |
Target |
Mechanism CD20 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date12 May 2023 |
Target |
Mechanism JAK1 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date06 Nov 2012 |
Target |
Mechanism PDL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Etanercept biosimilar (Hisun Bio Pharmaceutical Co., Ltd.) ( LTα x TNF-α ) | Rheumatoid Arthritis More | Approved |
Infliximab Biosimilar(Hisun Bio Pharmaceutical Co., Ltd.) ( TNF-α ) | Colitis, Ulcerative More | Approved |
Zuberitamab ( CD20 ) | CD20 positive Diffuse Large B-Cell Lymphoma More | Approved |
Adalimumab biosimilar(Hisun Pharmaceutical) ( TNF-α ) | Rheumatoid Arthritis More | Approved |
Tocilizumab biosimilar (Zhejiang Hisun) ( IL-6RA ) | Cytokine Release Syndrome More | Approved |